Altimmune, Inc. - Common Stock (NQ:ALT)

2.660 -0.010 (-0.37%)

Delayed Quote Updated: 1:57 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Altimmune, Inc. - Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Nasdaq Surges 100 Points; Crude Oil Rises 2% ↗

September 14, 2022

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Wednesday.

Via Benzinga

Twilio (TWLO) Stock Gains 6% on Layoff News ↗

September 14, 2022

Twilio (TWLO) stock is rising on Wednesday after the programmable communication tools company revealed plans to lay off employees.

Via InvestorPlace

Nucor, Altimmune And Some Other Big Stocks Moving Lower On Wednesday ↗

September 14, 2022

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Wednesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Altimune (ALT) Stock Plummets 33% Despite Positive Clinical Data ↗

September 14, 2022

Altimune (ALT) stock is falling hard on Wednesday even after reporting positive results from a Phase 1b clinical trial this morning.

Via InvestorPlace

US Stocks Open Higher, Producer Prices Decline for 2nd Month ↗

September 14, 2022

U.S. stocks traded higher this morning, following the release of PPI data for August.

Via Benzinga

Altimmune Shares Fall Despite Fatty Liver Disease Study Meets Primary Goal ↗

September 14, 2022

Via Benzinga

Altimmune: Q1 Earnings Insights ↗

May 12, 2022

Altimmune (NASDAQ:ALT) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Altimmune: Q4 Earnings Insights ↗

March 15, 2022

Altimmune (NASDAQ:ALT) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Altimmune Stock Is Tanking: What's Going On? ↗

September 14, 2022

Altimmune Inc (NASDAQ: ALT) shares are falling Wednesday morning. The company announced topline results from its 12-week Phase 1b study of pemvidutide in subjects with non-alcoholic fatty liver...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 14, 2022

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

September 13, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome ↗

August 30, 2022

Not all shares are slowing down alongside the industry group.

Via Investor's Business Daily

B. Riley Securities Maintains Buy Rating for Altimmune: Here's What You Need To Know ↗

August 12, 2022

B. Riley Securities has decided to maintain its Buy rating of Altimmune (NASDAQ:ALT) and raise its price target from $21.00 to $26.00. Shares of Altimmune are trading up 23.53% over the last 24...

Via Benzinga

Altimmune's Earnings Outlook ↗

March 11, 2022

Altimmune (NASDAQ:ALT) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement. Analysts estimate...

Via Benzinga

Altimmune's Mid-Stage Pemvidutide Study Cleared By FDA For Obesity ↗

January 31, 2022

The FDA has cleared Altimmune Inc's (NASDAQ:

Via Benzinga

Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday ↗

August 15, 2022

Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results.

Via Benzinga

Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday's Mid-Day Session ↗

August 12, 2022

Gainers Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over year.

Via Benzinga

LegalZoom.com, Toast And Some Other Big Stocks Moving Higher On Friday ↗

August 12, 2022

WeTrade Group, Inc. (NASDAQ: WETG) jumped 46% to $20.56 after the company announced it entered into a sales agreement with Parkway Medical Limited to sell monkeypox virus test kits and antigen tests...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 03, 2022

Via Benzinga

7 Biotech Stocks to Buy for Q3 ↗

July 18, 2022

These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential.

Via InvestorPlace

Piper Sandler Maintains Overweight Rating for Altimmune: Here's What You Need To Know ↗

May 18, 2022

Piper Sandler has decided to maintain its Overweight rating of Altimmune (NASDAQ:ALT) and lower its price target from $34.00 to $25.00. Shares of Altimmune are trading down 0.57% over the last 24...

Via Benzinga

89 Biggest Movers From Friday ↗

June 21, 2022

Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.

Via Benzinga

69 Biggest Movers From Yesterday ↗

June 10, 2022

Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares climbed 189.9% to close at $1.12 on Thursday.

Via Benzinga

The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More ↗

May 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

110 Biggest Movers From Friday ↗

May 16, 2022

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital.

Via Benzinga

The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More ↗

May 09, 2022

Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ:...

Via Benzinga

Altimmune Earnings Perspective: Return On Capital Employed ↗

March 16, 2022

According to Benzinga Pro data, during Q4, Altimmune (NASDAQ:ALT) posted sales of $3.28 million. Earnings were up 28.71%, but Altimmune still reported an overall loss of $23.89...

Via Benzinga

The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial ↗

March 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Scheduled For March 14, 2022 ↗

March 14, 2022

Companies Reporting Before The Bell • F45 Training Holdings (NYSE:FXLV) is projected to report earnings for its fourth quarter. • The One Group Hospitality (...

Via Benzinga

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗

March 13, 2022

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...

Via Benzinga

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.